Drug intelligence / Profile preview

IgYGate DC-PG

Development stage
Unknown
Lead developer
EW Nutrition Japan
Modality
Antibody-Based Therapeutics, Small Molecules
Administration
Oral
01

Overview

IgYGate DC-PG is a functional health food and oral care dietary supplement formulated as lozenges to support teeth and gum health. Developed by EW Nutrition Japan and distributed by Dong Do Pharmaceutical, the product contains two specific egg yolk immunoglobulin Y (IgY) antibodies, Ovalgen DC and Ovalgen PG, alongside xylitol. Ovalgen DC targets the glucosyltransferase (GTase) enzyme of *Streptococcus mutans* to inhibit bacterial adhesion and dental plaque formation, thereby preventing dental caries. Ovalgen PG targets the gingipain protease of *Porphyromonas gingivalis* to prevent gum tissue degradation and inflammation, thereby supporting the prevention and treatment of gingivitis and periodontitis. Xylitol acts synergistically to neutralize oral acids and reduce bacterial growth.

Brand names
IgYGate DC-PG
Other names
IgYGate DC-PCViên ngậm IgYGate DC-PG
02

Targets

Rgp (Arginine gingipain)Gtf (Streptococcus mutans glucosyltransferase)

Beyond the preview

Go deeper on IgYGate DC-PG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgYGate DC-PG.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call